TABLE 3.
Basal period | Final 30 min of exercise | |
---|---|---|
Lactate (mmol/l) | ||
anteEugly | 0.8 ± 0.1 | 1.9 ± 0.2* |
anteHypo | 0.8 ± 0.1 | 1.3 ± 0.1*† |
anteCort1 | 0.7 ± 0.1 | 1.1 ± 0.2*† |
anteCort2 | 0.9 ± 0.1 | 1.9 ± 0.1* |
Alanine (μmol/l) | ||
anteEugly | 329 ± 34 | 418 ± 43* |
anteHypo | 330 ± 32 | 367 ± 30* |
anteCort1 | 310 ± 60 | 360 ± 40* |
anteCort2 | 378 ± 32 | 419 ± 29* |
β-hydroxybutyrate (μmol/l) | ||
anteEugly | 40 ± 10 | 61 ± 10* |
anteHypo | 48 ± 13 | 66 ± 18 |
anteCort1 | 37 ± 5 | 51 ± 10 |
anteCort2 | 50 ± 10 | 40 ± 10† |
NEFA (μmol/l) | ||
anteEugly | 143 ± 25 | 383 ± 72* |
anteHypo | 227 ± 42‡ | 298 ± 48† |
anteCort1 | 148 ± 21 | 219 ± 61† |
anteCort2 | 149 ± 28 | 199 ± 39† |
Glycerol (μmol/l) | ||
anteEugly | 44 ± 9 | 145 ± 18* |
anteHypo | 48 ± 10 | 111 ± 16*† |
anteCort1 | 77 ± 20 | 111 ± 21*† |
anteCort2 | 50 ± 13 | 100 ± 14*† |
Data are means ± SEM. n = 22 type 1 diabetic subjects (11 men/11 women).
*Significant difference versus basal level (P < 0.05).
†Significantly reduced versus anteEugly (P < 0.05).
‡Significantly increased compared with other groups (P < 0.05).